Scarica l'app Stockscreener
176.28
5.85%
9.825
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics rises on upbeat results, guidance raise (DGX:NYSE) - Seeking Alpha
Quest Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises - Zacks Investment Research
Quest Diagnostics' Q2 2025 Earnings: A Strategic Analysis of Its Position in the Evolving Diagnostic Services Landscape - AInvest
Quest Diagnostics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com Canada
Quest Diagnostics (DGX) Boosts FY25 Revenue Outlook Amid Growth and Efficiency Gains | DGX Stock News - GuruFocus
Quest Diagnostics (DGX) Exceeds Revenue Expectations in Strong Q - GuruFocus
Quest Diagnostics Inc (DGX) Q2 2025 Earnings: EPS of $2.47 Beats Estimates, Revenue Hits $2.76 Billion - GuruFocus
Quest (NYSE:DGX) Surprises With Q2 Sales - FinancialContent
Quest Diagnostics Reports Second Quarter 2025 Financial Results - TradingView
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - PR Newswire
What analysts say about Quest Diagnostics Incorporated stockFree Predictions - Autocar Professional
Quest Diagnostics Earnings Preview: EPS Estimate $2.57, Neutral Consensus Rating, and 12.46% Upside Potential. - AInvest
Quest Diagnostics Earnings Preview - Nasdaq
Should You Buy Quest Diagnostics Ahead of Earnings? - Yahoo Finance
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance? - Yahoo Finance
Quest (DGX) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Quest Diagnostics Incorporated Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
Quest Diagnostics (DGX) Maintains Neutral Rating Amid Slight PT Adjustment | DGX Stock News - GuruFocus
Quest Diagnostics: UBS Keeps Neutral Rating, Lowers PT to $175 from $176 - AInvest
Quest Diagnostics (DGX) Faces Slight Price Target Adjustment by UBS | DGX Stock News - GuruFocus
What drives Quest Diagnostics Incorporated stock priceHigh-octane investment gains - Jammu Links News
11th Circ. Says Ex-Quest Diagnostics Worker's FCA Suit Fails - Law360
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Quest Lab Worker Fails to Revive Billing Fraud Suit on Appeal - Bloomberg Law News
Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test - MedTech Dive
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Quest Diagnostics launches test for Oropouche virus amid spread in Americas - Investing.com Canada
Quest Diagnostics (DGX) Launches Oropouche Virus Test | DGX Stoc - GuruFocus
Quest Diagnostics Introduces Testing for Oropouche Virus - MarketScreener
First-Ever Commercial Test for Dangerous Oropouche Virus Launches as Disease Spreads in Americas - Stock Titan
Quest Diagnostics: Buy Into Future Patient Demand, Undervalued Price Today (DGX) - Seeking Alpha
Quest Diagnostics launches test for Oropouche virus detection in United States; company's California lab will perform PCR testing for emerging disease starting late July 2025 - Industry Intelligence Inc.
Despite Slump, Options Traders May Be Seeing Something With Quest Diagnostics (DGX) - Barchart.com
Quest Diagnostics (DGX) Develops MCaST Blood Test with MD Anderson Cancer Center - Yahoo Finance
Quest Diagnostics Stock Drops 2.51% Amid Analyst Upgrade - AInvest
Quest Diagnostics Surges to 417th in Trading Volume with 2.25 Billion Shares Traded - AInvest
Quest Diagnostics (DGX) Launches FDA-Approved Alzheimer's Test - GuruFocus
Quest Diagnostics to offer Fujirebio Alzheimer's diagnostic test - Seeking Alpha
Quest Diagnostics Launches Revolutionary FDA-Cleared Blood Test to Detect Early Alzheimer's with 97% Accuracy - Stock Titan
Leerink Partners Adjusts PT on Quest Diagnostics to $192 From $189, Maintains Outperform Rating - MarketScreener
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It? - Nasdaq
Ex-Dividend Reminder: Edison International, Quest Diagnostics and Cousins Properties - Nasdaq
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant - TradingView
Quest Diagnostics tops NJ life sciences employer list - NJBIZ
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now? - Nasdaq
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - inkl
What To Expect From Quest Diagnostics' Q2 2025 Earnings Report - Barchart.com
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Nasdaq
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
DGX Stock Up on New Blood Test Development Deal With MD Anderson - MSN
Quest Diagnostics Transforms Healthcare Access: $13M in Grants, 1M Free Tests, and 50 New Diagnostic Services - Stock Titan
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025 – Company Announcement - Financial Times
Is Quest Diagnostics Stock Outperforming the Nasdaq? - MSN
Is Quest Diagnostics Stock Outperforming The Nasdaq? - Barchart.com
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Quest Diagnostics stock hits all-time high of $180.11 By Investing.com - Investing.com Canada
Quest partners with MD Anderson to develop cancer risk blood test - MedTech Dive
Quest Diagnostics and University of Texas want to promote more cancer screenings - Mugglehead Magazine
Fecal Immunochemical Diagnostic Test (FIT) Market Top - openPR.com
Quest Diagnostics (DGX) Collaborates with MD Anderson for Cancer Risk Test Development | DGX Stock News - GuruFocus
Quest Diagnostics New Blood Test Could Transform Early Cancer Detection for 9 Major Cancers - Stock Titan
Quest Diagnostics Incorporated : The stock forcefully approaches new pivot levels - MarketScreener
0.60%
3.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):